Fulvestrant: an oestrogen receptor antagonist with a novel mechanism of action

被引:0
|
作者
C K Osborne
A Wakeling
R I Nicholson
机构
[1] Baylor College of Medicine,Departments of Medicine and Molecular & Cellular Biology
[2] AstraZeneca Pharmaceuticals,undefined
[3] Tenovus Centre for Cancer Research,undefined
[4] Welsh School of Pharmacy,undefined
来源
British Journal of Cancer | 2004年 / 90卷
关键词
fulvestrant; ‘Faslodex’; oestrogen receptor antagonist; mechanism of action; advanced breast cancer;
D O I
暂无
中图分类号
学科分类号
摘要
Due to their favourable tolerability profiles, endocrine therapies have long been considered the treatment of choice for hormone-sensitive metastatic breast cancer. However, the oestrogen agonist effects of the available selective oestrogen receptor modulators, such as tamoxifen, and the development of cross-resistance between endocrine therapies with similar modes of action have led to the need for new treatments that act through different mechanisms. Fulvestrant (‘Faslodex’) is the first of a new type of endocrine treatment – an oestrogen receptor (ER) antagonist that downregulates the ER and has no agonist effects. This article provides an overview of the current understanding of ER signalling and illustrates the unique mode of action of fulvestrant. Preclinical and clinical study data are presented in support of the novel mechanism of action of this new type of ER antagonist.
引用
收藏
页码:S2 / S6
相关论文
empty
未找到相关数据